Please assess the completion status of the following clinical trial:

Trial Title: Study of Safety and Tolerability of DCR HBVS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 22.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy at the time of screening as determined by medical evaluation.~* Capable of giving informed consent.~* 12-lead ECG within normal limits or with no clinically significant abnormalities.~* Negative screen for alcohol or drugs of abuse.~* Non-smokers for at least 3 months with a negative urinary cotinine concentration at screening.~* BMI within range 18.0 - 32.0 kg/m2 (inclusive).~* Female participants not pregnant, not breastfeeding, and not of childbearing potential or willing to follow contraceptive guidance.~* Chronic hepatitis B infection (Group B and C only).~* Clinical history compatible with compensated liver disease with no evidence of cirrhosis (Group B and C only).~* Continuously on nucleotides (NUC) therapy for at least 12 weeks prior to screening (Group C only).~Exclusion Criteria:~* History of any medical condition that may interfere with the absorption, distribution, or elimination of study drug.~* Poorly controlled or unstable hypertension.~* History of diabetes mellitus treated with insulin or hypoglycemic agents.~* History of asthma requiring hospital admission within the preceding 12 months.~* Evidence of G-6-PD deficiency.~* Currently poorly controlled endocrine conditions, excluding thyroid conditions.~* History of multiple drug allergies or history of allergic reaction to an oligonucleotide or GalNAc.~* Clinically relevant surgical history.~* Use of prescription medications (excluding contraception for women) within 4 weeks prior to the administration of study intervention.~* Use of clinically relevant over-the-counter medication or supplements (excluding routine vitamins) within 7 days of first dosing.~* Has received an investigational agent within the 3 months prior to dosing or is in follow-up of another study.~* Antiviral therapy (other than entecavir or tenofovir) within 3 months of screening or treatment with interferon in the last 3 years (Group B and C only).~* Use within the last 6 months of anticoagulants or systemically administered corticosteroids, immunomodulators, or immunosuppressants (Group B and C only).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Cohort A1 DCR-HBVS (Type: EXPERIMENTAL): Single dose, Subcutaneous injection of 0.1mg/kg of DCR-HBVS (HV)
- Cohort A1 Placebo (Type: PLACEBO_COMPARATOR): Single dose, Subcutaneous injection of 0.1mg/kg of Placebo for DCR-HBVS (HV)
- Cohort A2 DCR-HBVS (Type: EXPERIMENTAL): Single dose, Subcutaneous injection of 1.5mg/kg of DCR-HBVS (HV)
- Cohort A2 Placebo (Type: PLACEBO_COMPARATOR): Single dose, Subcutaneous injection of 1.5mg/kg of Placebo for DCR-HBVS (HV)
- Cohort A3 DCR-HBVS (Type: EXPERIMENTAL): Single dose, Subcutaneous injection of 3mg/kg of DCR-HBVS (HV)
- Cohort A3 Placebo (Type: PLACEBO_COMPARATOR): Single dose, Subcutaneous injection of 3mg/kg of Placebo for DCR-HBVS (HV)
- Cohort A4 DCR-HBVS (Type: EXPERIMENTAL): Single dose, Subcutaneous injection of 6mg/kg of DCR-HBVS (HV)
- Cohort A4 Placebo (Type: PLACEBO_COMPARATOR): Single dose, Subcutaneous injection of 6mg/kg of Placebo for DCR-HBVS (HV)
- Cohort A5 DCR-HBVS (Type: EXPERIMENTAL): Single dose, Subcutaneous injection of 12mg/kg of DCR-HBVS (HV)
- Cohort A5 Placebo (Type: PLACEBO_COMPARATOR): Single dose, Subcutaneous injection of 12mg/kg of Placebo for DCR-HBVS (HV)
- Cohort B DCR-HBVS (Type: EXPERIMENTAL): Single dose, Subcutaneous injection of 3mg/kg of for DCR-HBVS (NUC naïve, CHB)
- Cohort B Placebo (Type: PLACEBO_COMPARATOR): Single dose, Subcutaneous injection of 3mg/kg of Placebo for DCR-HBVS (NUC naïve, CHB)
- Cohort C1 DCR-HBVS (Type: EXPERIMENTAL): 4 doses- Subcutaneous injection of 1.5mg/kg of DCR-HBVS administered every 28 days (NUC experienced, CHB)
- Cohort C1 Placebo (Type: PLACEBO_COMPARATOR): 4 doses- Subcutaneous injection of 1.5mg/kg of Placebo for DCR-HBVS administered every 28 days (NUC experienced, CHB)
- Cohort C2 DCR-HBVS (Type: EXPERIMENTAL): 4 doses- Subcutaneous injection of 3mg/kg of DCR-HBVS administered every 28 days (NUC experienced, CHB)
- Cohort C2 Placebo (Type: PLACEBO_COMPARATOR): 4 doses- Subcutaneous injection of 3mg/kg of Placebo for DCR-HBVS administered every 28 days (NUC experienced, CHB)
- Cohort C3 DCR-HBVS (Type: EXPERIMENTAL): 4 doses- Subcutaneous injection of 6mg/kg of DCR-HBVS administered every 28 days (NUC experienced, CHB)
- Cohort C3 Placebo (Type: PLACEBO_COMPARATOR): 4 doses- Subcutaneous injection of 6mg/kg of Placebo for DCR-HBVS administered every 28 days (NUC experienced, CHB)
- Cohort 4C DCR-HBVS (Type: EXPERIMENTAL): 1 dose- Subcutaneous injection of 100mg (NUC experienced, CHB)~1 dose- Subcutaneous injection of 200mg (NUC experienced, CHB)~1 dose- Subcutaneous injection of 400mg (NUC experienced, CHB)
- Cohort 5C1 DCR-HBVS (Type: EXPERIMENTAL): 4 doses- Subcutaneous injection of 200mg administered every 4 weeks (NUC experienced, CHB)
- Cohort 5C2 DCR-HBVS (Type: EXPERIMENTAL): 2 doses- Subcutaneous injection of 200mg administered every 8 weeks (NUC experienced, CHB)
- Cohort 5C3 DCR-HBVS (Type: EXPERIMENTAL): 2 doses- Subcutaneous injection of 400mg administered every 12 weeks (NUC experienced, CHB)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete